Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Microbot Medical ( (MBOT) ) is now available.
On April 22, 2026, Microbot Medical highlighted newly updated joint guidelines on occupational protection in interventional radiology issued by the Society of Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. Published in CardioVascular and Interventional Radiology, the guidelines expand safety recommendations for physicians and staff, including new provisions on radiation protection during pregnancy.
The company said the guidelines, now endorsed by at least nine medical societies, underscore the growing focus on reducing radiation exposure and musculoskeletal strain among interventional specialists. This trend aligns with the remote, radiation‑sparing design of Microbot’s LIBERTY robotic system, potentially strengthening its commercial appeal as hospitals seek solutions to health risks, staffing shortages and ergonomic challenges in endovascular and interventional radiology practices.
Microbot also pointed to broader professional backing for occupational radiation protection, including a late‑2025 policy from the American Medical Association calling for stronger safeguards and more research on cumulative exposure. The convergence of clinical guidance and policy support may reinforce demand for technologies like LIBERTY that allow operators to work away from radiation sources and in more ergonomic conditions, with possible implications for workforce retention and increased participation of women in the field.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the first FDA-cleared single-use, remotely operated robotic solution designed to enhance precision, efficiency and safety in endovascular care.
Average Trading Volume: 2,141,136
Technical Sentiment Signal: Sell
Current Market Cap: $154.5M
For a thorough assessment of MBOT stock, go to TipRanks’ Stock Analysis page.